Mayo Clinic Laboratory and Pathology Research Roundup: Aug. 15

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including a featured article of the week, abstracts, and complete list of published studies and reviews.

Featured Abstracts

Should Apolipoprotein B Replace LDL Cholesterol as Therapeutic Targets Are Lowered?

cardio-960x540The success of LDL cholesterol (LDL-C) as a predictor of atherosclerotic cardiovascular disease and a therapeutic target is indisputable. Apolipoprotein B (ApoB) is a more contemporary and physiologically relevant measure of atherogenic lipoproteins. Mayo Clinic researchers summarized recent comparisons of ApoB and LDL-C as biomarkers of cardiovascular risk. According to the results, ApoB is more analytically robust and standardized biomarker than LDL-C. Large population studies have found that ApoB is at worst clinically equivalent to LDL-C and likely superior when disagreement exists. Realistically, many obstacles prevent the wide spread adoption of ApoB and for now providers and their patients must weigh the costs and benefits of ApoB. The study was published in Current Opinion in Lipidology.

Radiogenomics to Characterize Regional Genetic Heterogeneity in Glioblastoma

testutilizationGlioblastoma exhibits profound intratumoral genetic heterogeneity. Each tumor comprises multiple genetically distinct clonal populations with different therapeutic sensitivities. This has implications for targeted therapy and genetically informed paradigms. Contrast-enhanced (CE)-MRI and conventional sampling techniques have failed to resolve this heterogeneity, particularly for nonenhancing tumor populations. Mayo Clinic researchers performed a study to explore the feasibility of using multiparametric MRI and texture analysis to characterize regional genetic heterogeneity throughout MRI-enhancing and nonenhancing tumor segments. Researchers found MRI and texture analysis can help characterize regional genetic heterogeneity, which offers potential diagnostic value under the paradigm of individualized oncology. The study was published in Neuro-oncology.

Published to PubMed This Week



Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.